Yahoo
    NasdaqGM - Nasdaq Real Time Price USD

    Aurinia Pharmaceuticals Inc. (AUPH)

    17.36 +0.11 (+0.64%)
    At close: October 28 at 4:00:01 PM EDT
    17.14 -0.22 (-1.26%)
    After hours: October 28 at 4:46:52 PM EDT
    Trade AUPH on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for AUPH
    • Previous Close 17.25
    • Open 17.10
    • Bid 12.84 x 100
    • Ask 17.28 x 100
    • Day's Range 17.05 - 17.38
    • 52 Week Range 11.96 - 19.25
    • Volume 623,393
    • Avg. Volume 930,773
    • Market Cap (intraday) 2.31B
    • Beta (5Y Monthly) 1.61
    • PE Ratio (TTM) 7.61
    • EPS (TTM) 2.28
    • Earnings Date (est.) Nov 9, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 18.00
    • Zacks Rating Neutral

    Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

    www.auriniapharma.com

    128

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Aurinia Pharmaceuticals Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    AUPH
    8.84%
    S&P 500 (^GSPC)
    13.13%

    1-Year Return

    AUPH
    37.45%
    S&P 500 (^GSPC)
    12.38%

    3-Year Return

    AUPH
    141.45%
    S&P 500 (^GSPC)
    88.08%

    5-Year Return

    AUPH
    42.06%
    S&P 500 (^GSPC)
    68.48%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue 83.22M
    Earnings 37.41M
    Profit Margin 44.96%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    0
    50M
    100M
    150M
    200M
    50.0%
    100.0%
    150.0%
    200.0%
    250.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    16.00 Low
    18.00 Average
    17.36 Current
    21.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/21/2026
    Analyst TD Cowen
    Rating Action Maintains
    Rating Buy
    Price Action Raises
    Price Target 17 -> 18
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      100.84%

    • Return on Assets (ttm)

      15.49%

    • Return on Equity (ttm)

      66.12%

    • Revenue (ttm)

      311.51M

    • Net Income Avi to Common (ttm)

      314.11M

    • Diluted EPS (ttm)

      2.28

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      443.02M

    • Total Debt/Equity (mrq)

      10.43%

    • Levered Free Cash Flow (ttm)

      147.82M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    TGTX TG Therapeutics, Inc.
    57.40 +1.70%
    AXSM Axsome Therapeutics, Inc.
    143.51 +0.92%
    OCUL Ocular Therapeutix, Inc.
    7.29 +8.48%
    KPTI Karyopharm Therapeutics Inc.
    0.8321 +73.35%
    ARDX Ardelyx, Inc.
    3.1000 +3.33%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: